EX-16.1 2 tm228806d1_ex16-1.htm EXHIBIT 16.1

Exhibit 16.1

 

March 9, 2022

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by Twist Bioscience Corporation (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Twist Bioscience Corporation dated March 3, 2022. We agree with the statements concerning our Firm contained therein.

 

Very truly yours,

 

/s/ PricewaterhouseCoopers LLP

 

San Jose, California

 

Attachment